|
DK0986382T3
(da)
*
|
1997-05-23 |
2008-10-20 |
Bayer Pharmaceuticals Corp |
RAF-kinasehæmmere
|
|
PT986382E
(pt)
*
|
1997-05-23 |
2008-07-10 |
Onyx Pharma Inc |
Inibidores de raf-quinase
|
|
US6187799B1
(en)
*
|
1997-05-23 |
2001-02-13 |
Onyx Pharmaceuticals |
Inhibition of raf kinase activity using aryl ureas
|
|
AU1924699A
(en)
|
1997-12-19 |
1999-07-12 |
Smithkline Beecham Corporation |
Compounds of heteroaryl substituted imidazole, their pharmaceutical compositionsand uses
|
|
ATE529109T1
(de)
*
|
1997-12-22 |
2011-11-15 |
Bayer Healthcare Llc |
Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
WO1999032463A1
(en)
*
|
1997-12-22 |
1999-07-01 |
Bayer Corporation |
INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US6858617B2
(en)
|
1998-05-26 |
2005-02-22 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
|
SE9802209D0
(sv)
|
1998-06-22 |
1998-06-22 |
Astra Pharma Inc |
Novel compounds
|
|
DE69914357T2
(de)
|
1998-11-04 |
2004-11-11 |
Smithkline Beecham Corp. |
Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
|
|
UY25842A1
(es)
*
|
1998-12-16 |
2001-04-30 |
Smithkline Beecham Corp |
Antagonistas de receptores de il-8
|
|
CA2549558C
(en)
*
|
1999-01-13 |
2010-08-31 |
Bayer Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1158985B1
(en)
*
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
|
PT1140840E
(pt)
*
|
1999-01-13 |
2006-05-31 |
Bayer Pharmaceuticals Corp |
Difenilureias substituidas com (.)-carboxiarilo como inibidores de raf-quinase
|
|
ME00275B
(me)
|
1999-01-13 |
2011-02-10 |
Bayer Corp |
ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
AU2004200566B2
(en)
*
|
1999-01-13 |
2006-08-17 |
Bayer Pharmaceuticals Corporation |
Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
CA2360934A1
(en)
*
|
1999-02-22 |
2000-08-31 |
Lin-Hua Zhang |
Polycyclo heterocyclic derivatives as antiinflammatory agents
|
|
EP1159273A1
(en)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
|
JP2002539206A
(ja)
*
|
1999-03-12 |
2002-11-19 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症剤としての芳香族複素環化合物
|
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
|
EP1690854A1
(en)
*
|
1999-03-12 |
2006-08-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
EP1466906A1
(en)
*
|
1999-03-12 |
2004-10-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
CN1148349C
(zh)
*
|
1999-04-07 |
2004-05-05 |
参天制药株式会社 |
N-取代-N′-取代脲衍生物及其用作TNF-α生成抑制剂的用途
|
|
US6573409B1
(en)
|
1999-07-02 |
2003-06-03 |
The Nutrasweet Company |
Process for the preparation of 3,3-dimethylbutanal
|
|
CN1360582A
(zh)
|
1999-07-07 |
2002-07-24 |
阿斯特拉曾尼卡英国有限公司 |
喹唑啉衍生物
|
|
CA2374737C
(en)
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
|
US6407238B1
(en)
*
|
1999-10-29 |
2002-06-18 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process of making substituted pyrazoles
|
|
EP1232150B1
(en)
|
1999-11-16 |
2007-10-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Urea derivatives as anti-inflammatory agents
|
|
EP1233950B1
(en)
|
1999-11-23 |
2005-10-05 |
Smithkline Beecham Corporation |
3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/P39 kINASE INHIBITORS
|
|
ATE281439T1
(de)
|
1999-11-23 |
2004-11-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
|
JP2003514900A
(ja)
|
1999-11-23 |
2003-04-22 |
スミスクライン・ビーチャム・コーポレイション |
ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４−ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
|
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
|
US7235551B2
(en)
|
2000-03-02 |
2007-06-26 |
Smithkline Beecham Corporation |
1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
|
US6822093B2
(en)
|
2000-05-23 |
2004-11-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US6635767B2
(en)
|
2000-05-23 |
2003-10-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US6414013B1
(en)
|
2000-06-19 |
2002-07-02 |
Pharmacia & Upjohn S.P.A. |
Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
|
|
WO2002000644A1
(en)
|
2000-06-24 |
2002-01-03 |
Astrazeneca Ab |
Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
AU9598601A
(en)
|
2000-10-20 |
2002-04-29 |
Eisai Co Ltd |
Nitrogenous aromatic ring compounds
|
|
JP2004517080A
(ja)
|
2000-11-29 |
2004-06-10 |
グラクソ グループ リミテッド |
Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
DE10109204A1
(de)
*
|
2001-02-26 |
2002-09-19 |
4Sc Ag |
Verbindungen zur Behandlung von Protozoen-Erkrankungen
|
|
EP1395548A1
(en)
|
2001-02-26 |
2004-03-10 |
4Sc Ag |
Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
JP2004530690A
(ja)
|
2001-05-16 |
2004-10-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症性薬剤として有用なジアリールウレア誘導体
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
|
US6881741B2
(en)
|
2001-06-11 |
2005-04-19 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
EP1709965A3
(en)
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
|
WO2003005999A2
(en)
*
|
2001-07-11 |
2003-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
US6924276B2
(en)
|
2001-09-10 |
2005-08-02 |
Warner-Lambert Company |
Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
|
|
EP1438048A1
(en)
*
|
2001-10-18 |
2004-07-21 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
|
US7030141B2
(en)
*
|
2001-11-29 |
2006-04-18 |
Christopher Franklin Bigge |
Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
US20040023961A1
(en)
*
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
|
EP1480973B1
(en)
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
ES2278170T3
(es)
|
2002-07-09 |
2007-08-01 |
BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG |
Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
|
|
DE10257358A1
(de)
*
|
2002-12-09 |
2004-07-08 |
Bayer Healthcare Ag |
Substituierte Pyrrole
|
|
KR101058696B1
(ko)
|
2002-12-10 |
2011-08-22 |
바이로켐 파마 인코포레이티드 |
후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
|
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
ATE552236T1
(de)
|
2003-01-14 |
2012-04-15 |
Cytokinetics Inc |
Verbindungen, zusammensetzungen und verfahren zur behandlung von herzinsuffizienz
|
|
GB0308511D0
(en)
*
|
2003-04-14 |
2003-05-21 |
Astex Technology Ltd |
Pharmaceutical compounds
|
|
MXPA05011503A
(es)
*
|
2003-04-25 |
2006-05-31 |
Johnson & Johnson |
Inhibidores de la c-fms cinasa.
|
|
EP1636585B2
(en)
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
WO2004113352A1
(en)
*
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
DE602004017478D1
(de)
|
2003-08-15 |
2008-12-11 |
Astrazeneca Ab |
Substituierte thiophene und deren verwendungen
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
US20060211752A1
(en)
|
2004-03-16 |
2006-09-21 |
Kohn Leonard D |
Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
|
|
DE102004015007A1
(de)
|
2004-03-26 |
2005-10-13 |
Bayer Healthcare Ag |
Substituierte Imidazole
|
|
EP2295426A1
(en)
|
2004-04-30 |
2011-03-16 |
Bayer HealthCare, LLC |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
ES2522579T3
(es)
|
2004-06-17 |
2014-11-17 |
Cytokinetics, Inc. |
Compuestos, composiciones y métodos
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
AU2005276117C1
(en)
|
2004-08-23 |
2013-04-18 |
Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science |
Peptide inhibitors for mediating stress responses
|
|
ATE428421T1
(de)
|
2004-09-17 |
2009-05-15 |
Eisai R&D Man Co Ltd |
Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
|
|
SG155229A1
(en)
*
|
2004-11-09 |
2009-09-30 |
Smithkline Beecham Corp |
Glycogen phosphorylase inhibitor compounds and pharmaceutical compositions thereof
|
|
US7612200B2
(en)
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US7741479B2
(en)
|
2004-12-07 |
2010-06-22 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of MAP kinases
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
DE102005008183A1
(de)
|
2005-02-23 |
2006-08-31 |
Bayer Healthcare Ag |
Heterocyclylamid-substituierte Imidazole
|
|
ATE482693T1
(de)
|
2005-03-07 |
2010-10-15 |
Bayer Schering Pharma Ag |
Pharmazeutische zusammensetzung mit einem omega- carboxyaryl-substituierten diphenylharnstoff zur behandlung von krebs
|
|
WO2006119646A1
(en)
|
2005-05-13 |
2006-11-16 |
Virochem Pharma Inc. |
Compounds and methods for the treatment or prevention of flavivirus infections
|
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
ES2419007T3
(es)
|
2005-12-15 |
2013-08-19 |
Cytokinetics, Inc. |
Ciertas entidades químicas, composiciones y procedimientos
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
WO2007078815A2
(en)
|
2005-12-16 |
2007-07-12 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
WO2007078839A2
(en)
|
2005-12-19 |
2007-07-12 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
JP2007254457A
(ja)
*
|
2006-02-23 |
2007-10-04 |
Daicel Chem Ind Ltd |
フラン化合物の製造法
|
|
CN104706637A
(zh)
|
2006-05-18 |
2015-06-17 |
卫材R&D管理有限公司 |
针对甲状腺癌的抗肿瘤剂
|
|
WO2008026748A1
(en)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Antitumor agent for undifferentiated gastric cancer
|
|
CA2676796C
(en)
|
2007-01-29 |
2016-02-23 |
Eisai R & D Management Co., Ltd. |
Composition for treatment of undifferentiated gastric cancer
|
|
KR20090115749A
(ko)
|
2007-02-26 |
2009-11-05 |
산텐 세이야꾸 가부시키가이샤 |
우레이드기와 아미노카르보닐기를 치환기로서 갖는 신규 피롤 유도체
|
|
WO2008131276A1
(en)
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
|
WO2010077955A1
(en)
|
2008-12-17 |
2010-07-08 |
The Scripps Research Institute |
Generation and maintenance of stem cells
|
|
MY162940A
(en)
|
2009-08-19 |
2017-07-31 |
Eisai R&D Man Co Ltd |
Quinoline derivative-containing pharmaceutical composition
|
|
CN102958523B
(zh)
|
2010-06-25 |
2014-11-19 |
卫材R&D管理有限公司 |
使用具有激酶抑制作用的组合的抗肿瘤剂
|
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
CA2836503C
(en)
|
2011-05-23 |
2020-09-22 |
Yeda Research And Development Co. Ltd. |
Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
WO2013162027A1
(ja)
|
2012-04-27 |
2013-10-31 |
学校法人 慶應義塾 |
神経分化促進剤
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
KR20150098605A
(ko)
|
2012-12-21 |
2015-08-28 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
퀴놀린 유도체의 비정질 형태 및 그의 제조방법
|
|
AU2014246866B2
(en)
|
2013-04-02 |
2018-05-10 |
Oxular Acquisitions Limited |
Kinase inhibitor
|
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
WO2015066490A1
(en)
|
2013-10-31 |
2015-05-07 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
ES2738693T3
(es)
*
|
2014-04-17 |
2020-01-24 |
Pasteur Institut Korea |
Compuestos para el tratamiento de infecciones virales
|
|
US10392381B2
(en)
|
2014-07-18 |
2019-08-27 |
Ohio University |
Prevention and treatment of non-alcoholic fatty liver disease
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
LT3263106T
(lt)
|
2015-02-25 |
2024-01-10 |
Eisai R&D Management Co., Ltd. |
Chinolino darinių kartumo sumažinimo būdas
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
MX373231B
(es)
|
2015-06-16 |
2020-05-08 |
Eisai R&D Man Co Ltd |
Agente anticancerigeno.
|
|
US12220398B2
(en)
|
2015-08-20 |
2025-02-11 |
Eisai R&D Management Co., Ltd. |
Tumor therapeutic agent
|
|
US12303505B2
(en)
|
2017-02-08 |
2025-05-20 |
Eisai R&D Management Co., Ltd. |
Tumor-treating pharmaceutical composition
|
|
RU2019134940A
(ru)
|
2017-05-16 |
2021-06-16 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Лечение гепатоцеллюлярной карциномы
|
|
IL276398B2
(en)
|
2018-01-31 |
2026-03-01 |
Deciphera Pharmaceuticals Llc |
Combination therapy for mastocytosis
|
|
CN118416236A
(zh)
|
2018-01-31 |
2024-08-02 |
德西费拉制药有限责任公司 |
治疗胃肠道间质瘤的组合疗法
|
|
CN109734677A
(zh)
*
|
2019-03-07 |
2019-05-10 |
四川大学 |
抑制组蛋白赖氨酸甲基转移酶nsd2的小分子化合物及其应用
|
|
WO2020185812A1
(en)
|
2019-03-11 |
2020-09-17 |
Teva Pharmaceuticals International Gmbh |
Solid state forms of ripretinib
|
|
EP4013412B1
(en)
|
2019-08-12 |
2026-01-28 |
Deciphera Pharmaceuticals, LLC |
Ripretinib for treating gastrointestinal stromal tumors
|
|
TWI878335B
(zh)
|
2019-08-12 |
2025-04-01 |
美商迪賽孚爾製藥有限公司 |
治療胃腸道基質瘤方法
|
|
EP4084779B1
(en)
|
2019-12-30 |
2024-10-09 |
Deciphera Pharmaceuticals, LLC |
Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
|
|
MX2022008103A
(es)
|
2019-12-30 |
2022-09-19 |
Deciphera Pharmaceuticals Llc |
Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
|
|
CN113717148B
(zh)
*
|
2020-05-25 |
2023-09-05 |
上海医药工业研究院 |
一种杂芳酰胺类化合物、其制备方法及应用
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|